睿知中国医院研究地图
候选清单

正在招募淋巴瘤I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies

ClinicalTrials.gov 上登记的一项淋巴瘤开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心华中科技大学同济医学院附属同济医院Tongji Hospital武汉医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06909474,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Relapsed within 12 months after achieving CR with first-line induction therapy.

    入选标准第 3 条

    Failure to achieve CR or relapse after ≥2 lines of chemotherapy.

    入选标准第 4 条

    Refractory to ≥2 lines of chemotherapy, primary resistance, or relapse post-HSCT.

    入选标准第 8 条

  3. Renal: Serum creatinine ≤2.0×ULN.

    入选标准第 10 条

    Hepatic: ALT/AST ≤3.0×ULN (≤5.0×ULN if liver involvement); total bilirubin ≤2.0×ULN.

    入选标准第 11 条

    HBV DNA > ULN (if HBsAg+ or HBcAb+).

    排除标准第 9 条

    HCV RNA > ULN (if HCV Ab+).

    排除标准第 10 条

  4. At least one bidimensionally measurable lesion per Lugano 2014 criteria: nodal lesions >1.5 cm in long axis; extranodal lesions >1.0 cm in long axis.

    入选标准第 7 条

  5. HIV+, syphilis+, or active tuberculosis.

    排除标准第 11 条

    Prior Malignancy: Within 5 years, except for cured cervical carcinoma in situ, basal/squamous skin cancer, localized prostate cancer, or ductal carcinoma in situ.

    排除标准第 18 条

  6. Pregnancy/Lactation: Pregnant, breastfeeding, or planning pregnancy within 1 year post-CAR-NK infusion.

    排除标准第 20 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);日常活动能力。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06909474,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. T-ALL Patients: Bone marrow morphology during screening shows ≥5% blasts/immature lymphocytes and/or flow cytometry confirms minimal residual disease (MRD)+, and meets any of the following:
  2. Refractory to ≥2 cycles of standard induction chemotherapy (failure to achieve CR).
  3. Relapsed within 12 months after achieving CR with first-line induction therapy.
  4. Failure to achieve CR or relapse after ≥2 lines of chemotherapy.
  5. Relapse after hematopoietic stem cell transplantation (HSCT).
  6. T-cell Lymphoma Patients: Confirmed diagnosis of T-lymphoblastic lymphoma (T-LBL) or T-cell non-Hodgkin lymphoma (including but not limited to: peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), extranodal NK/T-cell lymphoma (ENKL), T-cell prolymphocytic leukemia (T-PLL), adult T-cell leukemia/lymphoma (ATLL), mycosis fungoides/Sézary syndrome (MF/SS) stage IIB or higher), and meets both:
  7. At least one bidimensionally measurable lesion per Lugano 2014 criteria: nodal lesions >1.5 cm in long axis; extranodal lesions >1.0 cm in long axis.
  8. Refractory to ≥2 lines of chemotherapy, primary resistance, or relapse post-HSCT.
  9. Cardiac: Left ventricular ejection fraction (LVEF) ≥50% by echocardiography; no significant ECG abnormalities.
  10. Renal: Serum creatinine ≤2.0×ULN.
  11. Hepatic: ALT/AST ≤3.0×ULN (≤5.0×ULN if liver involvement); total bilirubin ≤2.0×ULN.
  12. Pulmonary: Oxygen saturation ≥92% (room air). 7.No Contraindications: To leukapheresis, venipuncture, or cell collection. 8.No Severe Psychiatric Disorders. 9.Contraception: Agreement to use effective contraception from informed consent until 1 year post-CAR-NK infusion (for patients of childbearing potential).

排除标准:Exclusion Criteria:

  1. Prior CAR-NK therapy or genetically modified cell therapy.
  2. Active CNS involvement at screening (prior CNS involvement with resolved status post-treatment is allowed).
  3. Recent Anticancer Therapy:
  4. Chemotherapy, targeted therapy, or investigational drugs within 2 weeks or 5 half-lives prior to screening.
  5. Radiotherapy within 2 weeks prior to screening.
  6. Active/Uncontrolled Infection: Within 1 week prior to screening.
  7. Cerebrovascular Event or Seizure: Within 6 months prior to screening.
  8. Viral Infections:
  9. HBV DNA > ULN (if HBsAg+ or HBcAb+).
  10. HCV RNA > ULN (if HCV Ab+).
  11. HIV+, syphilis+, or active tuberculosis.
  12. Cardiac Disease:
  13. NYHA Class III/IV congestive heart failure.
  14. Myocardial infarction or CABG ≤6 months prior.
  15. Clinically significant ventricular arrhythmia or unexplained syncope (excluding vasovagal/dehydration-related).
  16. Severe cardiomyopathy.
  17. Active/Uncontrolled Autoimmune Disease.
  18. Prior Malignancy: Within 5 years, except for cured cervical carcinoma in situ, basal/squamous skin cancer, localized prostate cancer, or ductal carcinoma in situ.
  19. Live Vaccination: Within 4 weeks prior to screening.
  20. Pregnancy/Lactation: Pregnant, breastfeeding, or planning pregnancy within 1 year post-CAR-NK infusion.
  21. Other: Investigator-determined ineligibility.

引自 ClinicalTrials.gov, NCT06909474, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06909474,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06909474